Quality of Life and Cost-Effectiveness Assessment of Radioiodine Ablation Strategies in Patients With Thyroid Cancer: Results From the Randomized Phase III ESTIMABL Trial
| dc.contributor.author | BORGET, Isabelle | |
| dc.contributor.author | BONASTRE, Julia | |
| dc.contributor.author | CATARGI, Bogdan | |
| dc.contributor.author | DEANDREIS, Desiree | |
| dc.contributor.author | ZERDOUD, Slimane | |
| dc.contributor.author | RUSU, Daniela | |
| dc.contributor.author | BARDET, Stephane | |
| dc.contributor.author | LEENHARDT, Laurence | |
| dc.contributor.author | BASTIE, Delphine | |
| dc.contributor.author | SCHVARTZ, Claire | |
| dc.contributor.author | VERA, Pierre | |
| dc.contributor.author | MOREL, Olivier | |
| dc.contributor.author | BENISVY, Daniele | |
| dc.contributor.author | BOURNAUD, Claire | |
| dc.contributor.author | BONICHON, Francoise | |
| dc.contributor.author | KELLY, Antony | |
| dc.contributor.author | TOUBERT, Marie-Elisabeth | |
| dc.contributor.author | LEBOULLEUX, Sophie | |
| dc.contributor.author | JOURNEAU, Florence | |
| dc.contributor.author | BENHAMOU, Ellen | |
| dc.contributor.author | SCHLUMBERGER, Martin | |
| dc.date.accessioned | 2020-09-03T08:02:19Z | |
| dc.date.available | 2020-09-03T08:02:19Z | |
| dc.date.issued | 2015 | |
| dc.identifier.issn | 0732-183X | |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/11013 | |
| dc.description.abstractEn | Purpose In the ESTIMABL phase III trial, the thyroid ablation rate was equivalent for the two thyroid-stimulating hormone (TSH) stimulation methods (thyroid hormone withdrawal [THW] and recombinant human TSH [rhTSH]) and the two iodine-131 (I-131) activities (1.1 or 3.7 GBq). The objectives of this article were to present health-related quality-of-life (HRQoL) results and a cost-effectiveness evaluation performed alongside this trial. Patients and Methods HRQoL and utility were longitudinally assessed, from random assignment to the follow-up visit at 8 +/- 2 months for the 752 patients with thyroid cancer, using the Short Form-36 and the EuroQoL-5D questionnaires, respectively. A cost-effectiveness analysis was performed from the societal perspective in the French context. Resource use (hospitalization for I-131 administration, rhTSH, sick leaves, and transportation) was collected prospectively. We used the net monetary benefit approach and computed cost-effectiveness acceptability curves for both TSH stimulation methods and I-131 activities. Sensitivity analyses of the costs of rhTSH were performed. Results At I-131 administration, THW caused a clinically significant deterioration of HRQoL, whereas HRQoL remained stable with rhTSH. This deterioration was transient with no difference 3 months later. rhTSH was more effective than THW in terms of quality-adjusted life-years (QALYs; +0.013 QALY/patient) but more expensive (+(sic)474/patient). The probability that rhTSH would be cost effective at a (sic)50,000/QALY threshold was 47% in France. The use of 1.1 GBq of I-131 instead of 3.7 GBq reduced per-patient costs by (sic)955 (US$1,018) but with slightly decreased efficacy (-0.007 QALY/patient). Conclusion rhTSH avoids the transient THW-induced deterioration of HRQoL but is unlikely to be cost effective at its current price. (C) 2015 by American Society of Clinical Oncology | |
| dc.language.iso | en | |
| dc.title.en | Quality of Life and Cost-Effectiveness Assessment of Radioiodine Ablation Strategies in Patients With Thyroid Cancer: Results From the Randomized Phase III ESTIMABL Trial | |
| dc.type | Article de revue | |
| dc.identifier.doi | 10.1200/jco.2015.61.6722 | |
| dc.subject.hal | Chimie/Matériaux | |
| bordeaux.journal | Journal of clinical oncology | |
| bordeaux.page | 2885-+ | |
| bordeaux.volume | 33 | |
| bordeaux.hal.laboratories | Institut de Chimie & de Biologie des Membranes & des Nano-objets (CBMN) - UMR 5248 | * |
| bordeaux.hal.laboratories | Institut de Chimie & de Biologie des Membranes & des Nano-objets (CBMN, UMR 5248) | |
| bordeaux.issue | 26 | |
| bordeaux.institution | Université de Bordeaux | |
| bordeaux.institution | Bordeaux INP | |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Journal%20of%20clinical%20oncology&rft.date=2015&rft.volume=33&rft.issue=26&rft.spage=2885-+&rft.epage=2885-+&rft.eissn=0732-183X&rft.issn=0732-183X&rft.au=BORGET,%20Isabelle&BONASTRE,%20Julia&CATARGI,%20Bogdan&DEANDREIS,%20Desiree&ZERDOUD,%20Slimane&rft.genre=article |
Files in this item
| Files | Size | Format | View |
|---|---|---|---|
|
There are no files associated with this item. |
|||